Related Experiment Video
Updated: May 24, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[New class of medicines for chronic hepatitis C]
Sem J Aronson1, Joep de Bruijne, Janke Schinkel
1Academisch Medisch Centrum, Afd. Maag-, Darm-, en Leverziekten, Amsterdam, the Netherlands.
Abstract:
Worldwide approximately 130-210 million people suffer from chronic hepatitis C. Adequate antiviral therapy reduces morbidity and mortality caused by chronic hepatitis C and prevents further spread of the hepatitis C-virus (HCV). The current standard treatment of chronic hepatitis C, consisting of the combination of pegylated interferon-α (peginterferon) and ribavirin, lasts 24-48 weeks, and is accompanied by significant side effects and has a suboptimal chance of success. Protease inhibitors, which have recently been registered, belong to a new class of medicines which directly affect the life cycle of HCV. Protease inhibitors, in combination with peginterferon and ribavirin, provide almost double the chance of curing in patients with HCV genotype 1. Treatment duration can be shortened in a considerable proportion of these patients. Since treatment with protease inhibitors can lead to resistant virus strains and this therapy leads to additional side effects, the complexity of treatment will increase.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Cirrhosis I: Introduction

